-
Mashup Score: 2FDA Approves Expanded Use for Trikafta in Cystic Fibrosis - 22 day(s) ago
Vanzacaftor/tezacaftor/deutivacaftor (Alyftek) also received approval for the treatment of cystic fibrosis in people 6 years and older who have at least 1 F508del mutation.
Source: www.pharmacytimes.comCategories: General Medicine News, General Journals & SocietTweet
Breaking News: The #FDA approved an expanded use for elexacaftor/tezacaftor/ivacaftor and ivacaftor (Trikafta; Vertex Pharmaceuticals Inc) for the treatment of individuals with cystic #fibrosis ages 2 and older who harbor certain mutations. Coverage here: https://t.co/Yycj4rInq4